GLP-1 Weight Loss Access — 2026 Update
The GLP-1 landscape is changing fast. We cut through the confusion — connecting you only with licensed telehealth providers offering FDA-authorized medications, transparently priced and physician supervised.
* Paragon Health Access is an independent affiliate operated by Paragon Frontier Capital LLC. All medical decisions are made by licensed providers. FTC-required disclosure: we may earn a commission when you enroll through our links.
Simple Process
We've vetted the top GLP-1 telehealth programs so you don't have to. Compare, choose, and connect in minutes.
Understand the difference between semaglutide and tirzepatide programs, pricing models, and what each telehealth provider offers.
Compare verified programs side-by-side. All providers are licensed and cover most US states with transparent monthly pricing.
Complete a quick medical intake form, consult with a licensed physician, and receive your medication directly at home.
Important 2026 Update
The FDA has significantly tightened rules around GLP-1 medications. Here's what you need to know before choosing a provider.
The FDA resolved semaglutide and tirzepatide shortages in early 2025 and ended grace periods for mass compounding by May 2025. In April 2026 the FDA proposed permanently excluding these drugs from large-scale compounding. Enforcement is actively ongoing.
Providers heavily dependent on compounded medications have faced FDA warning letters, lawsuits from Novo Nordisk and Eli Lilly, and forced business model changes. Patients on those programs may face disruption to their supply and pricing.
Branded GLP-1 medications — Wegovy, Ozempic, Zepbound, and Mounjaro — are FDA-approved with established safety profiles. Telehealth providers offering these medications through licensed physicians are on the right side of this regulatory shift.
Paragon Health Access editorial policy: We only feature telehealth providers offering FDA-authorized prescription GLP-1 medications dispensed through licensed physicians. We do not promote programs under active FDA enforcement action. All provider listings are reviewed regularly for compliance standing. This is informational only — not medical or legal advice.
Vetted Programs — 2026
Every program below is independently reviewed by our editorial team. We assess medication type, physician oversight, state coverage, and pricing transparency. We earn commissions when you enroll — disclosed in full on our Affiliate Disclosure page.
| Medication | GLP-1 & GIP-GLP-1 |
| Physician Oversight | ✓ Every prescription |
| Lab Testing | ✓ Included |
| State Coverage | Nationwide |
| Monthly Cost | Verify at site |
| FDA Status | ✓ No action |
| Medication | GLP-1 |
| Physician Oversight | ✓ Licensed MDs |
| Lab Testing | Verify at site |
| State Coverage | Nationwide |
| Monthly Cost | Verify at site |
| FDA Status | ✓ No action |
| Medication | GLP-1 |
| Physician Oversight | ✓ Licensed MDs |
| State Coverage | Nationwide |
| Approval Speed | ✓ Fast |
| Monthly Cost | Verify at site |
| Lab Testing | Verify at site |
| Medication | GLP-1 |
| Physician Oversight | ✓ Every prescription |
| Lab Testing | Verify at site |
| State Coverage | ✓ All 50 states |
| Monthly Cost | Verify at site |
| FDA Status | ✓ No action |
All program details verified May 2026. Pricing, availability, and terms change frequently — always confirm directly with each provider before enrolling. We earn commissions on referrals — see our full disclosure.
Why Paragon
We built Paragon Health Access because navigating GLP-1 providers is confusing — pricing is opaque, claims are exaggerated, and options are overwhelming.
Every provider is vetted for licensing, pricing transparency, and patient support before we list them.
Following the 2025–2026 FDA enforcement wave against compounded GLP-1s, we feature only providers offering FDA-authorized branded medications through licensed physicians.
We provide education and honest comparisons. The decision is always yours — we never collect your personal health data.
Quick Check
Answer 4 quick questions to see which type of program may suit you. Takes under 60 seconds.
The Science
Published trials show average body weight reductions of 15–20% over 68–72 weeks for semaglutide and tirzepatide respectively — substantially greater than lifestyle intervention alone.
Clinical averages reflect large trial populations. Your individual results will depend on your starting weight, adherence, metabolic factors, and physician guidance. Some participants saw greater results; others less.
All trial participants were under physician supervision. GLP-1 medications have known side effects and contraindications. Only a licensed provider can determine whether this treatment is appropriate for you.
Free 2026 Resource
Free breakdown of the FDA regulatory changes, which programs are still legitimate, and how to find a safe GLP-1 provider. Delivered instantly to your inbox.
We respect your privacy. No spam — ever. Unsubscribe anytime. By submitting you agree to our Privacy Policy. Affiliate disclosure: emails may contain links to programs we are compensated for.
GLP-1 Resource Center
The GLP-1 landscape changed dramatically in 2026. Our editorial team breaks down what's legal, what's not, and how to choose a safe provider.
Get Started Today
Compare FDA-authorized GLP-1 programs from licensed telehealth providers — vetted for compliance, pricing transparency, and physician quality.
Affiliate Disclosure: Paragon Health Access is operated by Paragon Frontier Capital LLC, a Delaware limited liability company. We earn commissions from telehealth providers when you enroll through our referral links. This does not affect our editorial assessments. All medical decisions are made by licensed healthcare providers, not by Paragon Health Access. We do not provide medical advice.